Re: Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial

被引：1
|
作者：
Sonpavde, Guru [1 ,2 ]
Pal, Sumanta [3 ]
机构：
[1] Univ Alabama UAB, Sch Med, Hematol Oncol Sect, Dept Med, Birmingham, AL USA
[2] Vet Affairs Med Ctr, Birmingham, AL USA
[3] City Hope Comprehens Canc Ctr, Dept Med, Hematol Oncol Sect, Duarte, CA USA
来源：
EUROPEAN UROLOGY | 2016年 / 70卷 / 01期
关键词：
CANCER;
D O I：
10.1016/j.eururo.2016.03.057
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：203 / 203
页数：1
相关论文
共 43 条
  • [41] Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial (vol 18, pg 672, 2017)
    Garcia-Donas, J.
    Font, A.
    Perez-Valderrama, B.
    LANCET ONCOLOGY, 2019, 20 (01): : E9 - E9
  • [42] Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
    Al-Batran, Salah-Eddin
    Hofheinz, Ralf D.
    Pauligk, Claudia
    Kopp, Hans-Georg
    Haag, Georg Martin
    Luley, Kim Barbara
    Meiler, Johannes
    Homann, Nils
    Lorenzen, Sylvie
    Schmalenberg, Harald
    Probst, Stephan
    Koenigsmann, Michael
    Egger, Matthias
    Prasnikar, Nicole
    Caca, Karel
    Trojan, Joerg
    Martens, Uwe M.
    Block, Andreas
    Fischbach, Wolfgang
    Mahlberg, Rolf
    Clemens, Michael
    Illerhaus, Gerald
    Zirlik, Katja
    Behringer, Dirk M.
    Schmiegel, Wolff
    Pohl, Michael
    Heike, Michael
    Ronellenfitsch, Ulrich
    Schuler, Martin
    Bechstein, Wolf O.
    Koenigsrainer, Alfred
    Gaiser, Timo
    Schirmacher, Peter
    Hozaeel, Wael
    Reichart, Alexander
    Goetze, Thorsten O.
    Sievert, Mark
    Jaeger, Elke
    Moenig, Stefan
    Tannapfel, Andrea
    LANCET ONCOLOGY, 2016, 17 (12): : 1697 - 1708
  • [43] Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-label, Phase 3, Randomised Controlled Trial. Lancet 2019;393:2404-15 Putting IMmotion into Motion: Personalizing Frontline Treatment for Metastatic Renal Cell Carcinoma
    Singla, Nirmish
    EUROPEAN UROLOGY, 2020, 77 (06) : E168 - E169
12345